Drilldown: Medicines

Azithromycin (1) · Bisoprolol (1) · Fluconazole (1) · Irbesartan (1) · Nebivolol (1) · Telmisartan (1)

Avapro (1) · Bystolic (1) · Diflucan (1) · Micardis (1) · Zebeta (1) · Zithromax, Z-Pak, Zmax (1)

Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (2) · [[:Category:Antifungals|Antifungal (triazole)]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (2) · [[:Category:Azalides|Azalide]] (1) · [[:Category:Macrolide_antibiotics|Macrolide antibiotic]] (1) · [[:Category:Triazoles|Triazole]] (1)

None (2) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) · '"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1)

'"`UNIQ--vote-000003F6-QINU`"', '"`UNIQ--vote-000003F7-QINU`"', '"`UNIQ--vote-000003F8-QINU`"', '"`UNIQ--vote-000003F9-QINU`"', '"`UNIQ--vote-000003FA-QINU`"', '"`UNIQ--vote-000003FB-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) · '"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"' (1) · '"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1)

150 mg PO once daily; titrate to 300 mg if needed (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 40 mg PO once daily; titrate to 80 mg (1) · 5 mg daily (1) · 500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5 (1) · Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)

2.5, 5, 10, 20 mg tabs (1) · 20, 40, 80 mg tablets (1) · 250 mg, 500 mg, 600 mg tablets; 100, 200 mg/5 mL suspension; 2 g ER suspension (Zmax); 500 mg IV (1) · 5, 10 mg tabs (1) · 50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) · 75, 150, 300 mg tablets (1)

20 mg/d (1) · 300 mg/d (1) · 40 mg/d (1) · 500 mg/d (typical regimen); single 2 g for Zmax; 2 g for select STIs (1) · 80 mg/d (1) · 800 mg/d (severe invasive disease) (1)

IV (2) · Oral (6)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 h (2) · 24 hours (3) · Tissue half-life supports once-daily and post-treatment effect (1)

11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) · 9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) · ~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) · ~68 hours (terminal; reflects deep tissue accumulation, much longer than plasma)'"`UNIQ--ref-000003FC-QINU`"' (1)

42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) · 60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) · >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"' (1) · ~90% (low first-pass) (1)

None (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) · Category C (2) · Generally considered safe; commonly used in pregnancy when macrolide indicated.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (4)